- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07521007
En fas 2b klinisk prövning av YN001 hos vuxna med koronar ateroskleros (PURIFY-TIMI 81)
En randomiserad, multicentrisk, dubbelblind, parallell, placebokontrollerad fas 2b-klinisk prövning för att utvärdera effektiviteten och säkerheten hos YN001 hos vuxna med koronar ateroskleros
This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a multinational, multicenter, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of intravenously administered YN001 compared with placebo in participants with coronary atherosclerosis who are receiving background therapy for CV risk factors management.
A total of 456 participants are expected to be enrolled. The study will consist of a maximum 12-week screening/Baseline period, followed by a 12-week blinded treatment period, a 30-day safety follow-up, and a long-term follow-up period through Week 96 (approximately 2 years after randomization).
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Jingmei Zhang, Master
- Telefonnummer: 0086 010 82599080
- E-post: zhangjingmei@innovmedicine.com
Studera Kontakt Backup
- Namn: Kaiqi Zong, Master
- Telefonnummer: 0086 010 82599080
- E-post: zongkaiqi@innovmedicine.com
Studieorter
-
-
New South Wales
-
Penrith, New South Wales, Australien, 2750
- Rekrytering
- Cannopy Clinical Research
-
Kontakt:
- Karen Kaluhin, MD
- Telefonnummer: 0061 0491 276 512
- E-post: kkaluhin@canopycr.com.au
-
-
Queensland
-
Brisbane, Queensland, Australien, 4064
- Rekrytering
- Core Research Group Pty Ltd.
-
Kontakt:
- David Colquhou, MD
- Telefonnummer: 614-1184-2788
- E-post: d.colquhoun@uq.edu.au
-
-
Victoria
-
Altona N., Victoria, Australien, 3025
- Rekrytering
- Canopy Clinical Research
-
Kontakt:
- Oscar Walsh, MD
- Telefonnummer: 0061 03 9968 7601
- E-post: owalsh@canopycr.com.au
-
-
-
-
Alabama
-
Huntsville, Alabama, Förenta staterna, 35801-4312
- Rekrytering
- Heart Center Research, LLC
-
Kontakt:
- Walter Haught, MD
- Telefonnummer: 256-519-8472
- E-post: hhaught@theheartcenter.md
-
-
California
-
Covina, California, Förenta staterna, 91740
- Har inte rekryterat ännu
- Thrive Clinical Research Group, LLC
-
Kontakt:
- Sami Hayek
- Telefonnummer: 818-280-4220
- E-post: samihayek82@hotmail.com
-
Kontakt:
- E-post: shayek@foothillcardiology.com
-
Lincoln, California, Förenta staterna, 95648
- Har inte rekryterat ännu
- Clinical Trials Research
-
Kontakt:
- Jeffrey Wayne, MD
- Telefonnummer: 916-434-8230
- E-post: jwaynemd@ctrsites.com
-
Los Alamitos, California, Förenta staterna, 90720
- Har inte rekryterat ännu
- University of California Irvine Medical Center - Cardiovascular Center
-
Kontakt:
- Arnold Seto
- Telefonnummer: 562-598-3200
- E-post: arnold.seto@va.gov
-
Stanford, California, Förenta staterna, 94305-2200
- Har inte rekryterat ännu
- Stanford Health Care General Cardiology
-
Kontakt:
- Fahim Abbasi, MD
- Telefonnummer: 650-723-6459
- E-post: fahim@stanford.edu
-
Torrance, California, Förenta staterna, 90502-2006
- Rekrytering
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
Kontakt:
- Matthew Budoff, MD
- Telefonnummer: 310-222-3641
- E-post: mbudoff@lundquist.org
-
-
Florida
-
Boca Raton, Florida, Förenta staterna, 33434
- Har inte rekryterat ännu
- Flourish Research - Boca Raton
-
Kontakt:
- Richard Goldman
- Telefonnummer: 561-756-8206
- E-post: rgoldman@flourishresearch.com
-
Hialeah, Florida, Förenta staterna, 33016-1895
- Rekrytering
- New Generation of Medical Research, LLC.
-
Kontakt:
- Karelia Ruiz
- Telefonnummer: 305-828-9100
- E-post: kareliar@ngmresearch.com
-
St. Petersburg, Florida, Förenta staterna, 33709
- Rekrytering
- HCA Florida Heart Institute
-
Kontakt:
- Robert Sanchez, MD
- Telefonnummer: 727-490-2100
- E-post: robert.sanchez7@hcahealthcare.com
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30303-3049
- Har inte rekryterat ännu
- Emory Healthcare-Emory Heart & Vascular Center - Executive Park
-
Kontakt:
- Modele Ogunniyi
- Telefonnummer: 404-616-4440
- E-post: modele.ogunniyi@emory.edu
-
-
Idaho
-
Meridian, Idaho, Förenta staterna, 83642
- Har inte rekryterat ännu
- St. Luke's Clinic - Idaho Cardiology Associates
-
Kontakt:
- Brian Nolan
- Telefonnummer: 208-322-1680
- E-post: bnolan@slhs.org
-
-
Illinois
-
Springfield, Illinois, Förenta staterna, 62781
- Har inte rekryterat ännu
- Southern Illinois University School of Medicine
-
Kontakt:
- Abdul Hafiz, MD
- Telefonnummer: 217-545-8000
- E-post: ahafiz96@siumed.edu
-
-
Kansas
-
Overland Park, Kansas, Förenta staterna, 66211-1215
- Rekrytering
- Midwest Heart & Vascular Specialists, LLC
-
Kontakt:
- Stephen Bloom, MD
- Telefonnummer: 913-253-3000
- E-post: sbloom@kc.rr.com
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63110-1032
- Rekrytering
- WU School of Medicine - (CAM) - Heart and Vascular Center
-
Kontakt:
- Farhan Katchi, MD
- Telefonnummer: 314-362-1291
- E-post: katchif@wustl.edu
-
-
North Carolina
-
Raleigh, North Carolina, Förenta staterna, 27607
- Har inte rekryterat ännu
- NC Heart and Vascular Research, LLC
-
Kontakt:
- Mohit Pasi
- Telefonnummer: 919-784-2300
- E-post: mohit.pasi2@unchealth.unc.edu
-
Winston-Salem, North Carolina, Förenta staterna, 27104-3520
- Har inte rekryterat ännu
- Javara Inc. - Wake Forest University Health Sciences
-
Kontakt:
- Michael Shapiro, MD
- Telefonnummer: 336-713-7251
- E-post: owen.spitz@javararesearch.com
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45219
- Har inte rekryterat ännu
- The Christ Hospital
-
Kontakt:
- Mark Berlacher, MD
- Telefonnummer: 513-585-1777
- E-post: Mark.Berlacher@thechristhospital.com
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73135
- Har inte rekryterat ännu
- South Oklahoma Heart Research, LLC
-
Kontakt:
- Naeem Tahirkheli
- Telefonnummer: 405-628-6865
- E-post: ntahirkheli@okheart.com
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, Förenta staterna, 17011
- Rekrytering
- Capital Area Research, LLC - Camp Hill
-
Kontakt:
- Venkatesh Nadar, MD
- Telefonnummer: 717-695-8722
- E-post: VNadar@care-research.com
-
-
Texas
-
Amarillo, Texas, Förenta staterna, 79106
- Rekrytering
- PharmaTex Research, LLC
-
Kontakt:
- David Brabham
- Telefonnummer: 806-355-2581
- E-post: dgbrabham@hotmail.com
-
Carrollton, Texas, Förenta staterna, 75010
- Har inte rekryterat ännu
- Pulse Care Heart and Vascular
-
Kontakt:
- Kiran Kumar Mangalpally
- Telefonnummer: 214-407-8640
- E-post: trials@stryderesearch.com
-
Tomball, Texas, Förenta staterna, 77375
- Har inte rekryterat ännu
- DM Clinical Research - Dallas
-
Kontakt:
- Mustafa Mandviwala
- Telefonnummer: 346-550-9559
- E-post: drmandviwala.ns@dmclinical.com
-
-
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R2H 2A6
- Har inte rekryterat ännu
- St. Boniface Hospital
-
Kontakt:
- Shuangbo Liu
- Telefonnummer: 204-237-2793
- E-post: sliu@sbgh.mb.ca
-
-
Ontario
-
London, Ontario, Kanada, N5A 5A5
- Har inte rekryterat ännu
- London Health Sciences Centre
-
Kontakt:
- Habib Khan
- Telefonnummer: 519-663-3197
- E-post: habib.khan@lhsc.on.ca
-
North York, Ontario, Kanada, M6B 3H7
- Har inte rekryterat ännu
- North York Diagnostic and Cardiac Centre
-
Kontakt:
- Subodh Verma, MD
- Telefonnummer: 416-436-0244
- E-post: subodh.verma@unityhealth.to
-
Toronto, Ontario, Kanada, M5B 1W8
- Har inte rekryterat ännu
- St. Michael's Hospital
-
Kontakt:
- John Graham
- Telefonnummer: 416-864-6060
- E-post: John.Graham@unityhealth.to
-
Vaughan, Ontario, Kanada, L6A 4N9
- Har inte rekryterat ännu
- Cardiac Clinic
-
Kontakt:
- Navneet Singh
- Telefonnummer: 905-417-3001
- E-post: navneet.singh@thp.ca
-
-
Toronto
-
Toronto, Toronto, Kanada, M5G 2N2
- Har inte rekryterat ännu
- Toronto General Hospital - University Health Network
-
Kontakt:
- Jacob Udell
- Telefonnummer: 416-340-4800
- E-post: jay.udell@utoronto.ca
-
-
-
-
An
-
Hefei, An, Kina, 230022
- Rekrytering
- The First Affiliated Hospital of Anhui Medical Unversity
-
Kontakt:
- Jianlong Wang, MD
- Telefonnummer: 0086-13681292304
- E-post: Wjlmll@sina.com
-
-
Anhui
-
Hefei, Anhui, Kina, 230001
- Rekrytering
- Anhui Provincial Hospital
-
Kontakt:
- Kangyu Chen, MD
- Telefonnummer: 0086 18056005099
- E-post: ustccky@126.com
-
Huvudutredare:
- Kangyu Chen, MD
-
Underutredare:
- Chao Gao, MD
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100035
- Rekrytering
- Beijing Jishuitan Hospital
-
Huvudutredare:
- Wei Liu, MD
-
Kontakt:
- Qingwei Ji, MD
- Telefonnummer: 0086 18376642655
- E-post: jqwl24@163.cou
-
Huvudutredare:
- Qingwei Ji, MD
-
Beijing, Beijing Municipality, Kina, 100029
- Rekrytering
- Anzhen Hospital
-
Kontakt:
- Yuyang Liu, MD
- Telefonnummer: 0086 010-64456488
- E-post: liuyy803803@163.com
-
Huvudutredare:
- Yuyang Liu, MD
-
Beijing, Beijing Municipality, Kina, 101100
- Har inte rekryterat ännu
- Beijing Luhe Hospital
-
Kontakt:
- Guangyao Zhai, MD
- Telefonnummer: +86 1069543901
- E-post: drzhaiguangyao@163.com
-
-
Fujian
-
Fuzhou, Fujian, Kina, 350001
- Rekrytering
- Fujian Medical University Union Hospital
-
Kontakt:
- Mingfang Ye, MD
- Telefonnummer: 0086 13960818759
- E-post: xieheyemingfang@163.com
-
Huvudutredare:
- Mingfang Ye, MD
-
Underutredare:
- Zhaoyang Chen, MD
-
-
Gansu
-
Lanzhou, Gansu, Kina, 730030
- Rekrytering
- The Second Hospital & Clinical Medical School Lanzhou University
-
Kontakt:
- Feng Bai, MD
- Telefonnummer: 0086-13609363049
- E-post: baifeng@medmail.com.cn
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510080
- Rekrytering
- Guangdong Provincial People's Hospital
-
Kontakt:
- Ning Tan, MD
- E-post: tanning100@126.com
-
Kontakt:
- Telefonnummer: 0086-13903073651
- E-post: tangning100@126.com
-
-
Heilongjiang
-
Daqing, Heilongjiang, Kina, 163316
- Rekrytering
- Daqing People's Hospital
-
Kontakt:
- Shu Zhang
- Telefonnummer: +86-459-6612898
- E-post: dqsrmyygcp@163.com
-
Harbin, Heilongjiang, Kina, 150001
- Rekrytering
- The First Affiliated Hospital of Harbin Medical University
-
Kontakt:
- Lu Fu, MD
- Telefonnummer: 0086 137 9668 4968
- E-post: fuluyidayi@163.com
-
Huvudutredare:
- Lu Fu, MD
-
Huvudutredare:
- Yongtai Gong, MD
-
-
Hubei
-
Wuhan, Hubei, Kina, 430071
- Rekrytering
- Zhongnan Hospital of Wuhan University
-
Kontakt:
- Xiaorong Hu, MD
- Telefonnummer: 0086 15927681634
- E-post: huzrzn@whu.edu.cn
-
Huvudutredare:
- Xiaorong Hu, MD
-
-
Hunan
-
Changsha, Hunan, Kina, 410008
- Rekrytering
- The Second Xiangya Hospital fo Central South University
-
Kontakt:
- Xinqun Hu, MD
- Telefonnummer: 0086-13307313627
- E-post: huxinqungs@163.com
-
-
Jilin
-
Changchun, Jilin, Kina, 130033
- Rekrytering
- The First Hospital of Jilin University
-
Huvudutredare:
- Qian Tong, MD
-
Kontakt:
- Qian Tong, MD
- Telefonnummer: 0086 13074337289
- E-post: tongqian187@aliyun.com
-
-
Liaoning
-
Shenyang, Liaoning, Kina, 110015
- Rekrytering
- The People's Hospital of Liaoning Province
-
Huvudutredare:
- Ying Liu, MD
-
Kontakt:
- Ying Liu, MD
- Telefonnummer: 0086 13840065379
- E-post: liuyingwangli@126.com
-
-
Shaanxi
-
Xi'an, Shaanxi, Kina, 710068
- Rekrytering
- Shaanxi Provincial People's Hospital
-
Kontakt:
- Xiling Shou, MD
- Telefonnummer: 0086 18966700335
- E-post: shouxiling@163.com
-
-
Shandong
-
Jinan, Shandong, Kina
- Rekrytering
- Central Hospital Affiliated to Shandong First Medicial University
-
Kontakt:
- Guohai Su, MD
- Telefonnummer: 0086 19953193319
- E-post: gttstg@163.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200032
- Rekrytering
- Fudan University-Zhongshan Hospital
-
Huvudutredare:
- Junbo Ge, MD
-
Kontakt:
- Junbo Ge, MD
- Telefonnummer: 021-64041990
- E-post: ge.junbo@zs-hospital.sh.cn
-
Underutredare:
- Yuxiang Dai, MD
-
Shanghai, Shanghai Municipality, Kina, 200001
- Rekrytering
- Renji Hospital Shanghai Jiaotong University school of medicine
-
Kontakt:
- Jun Bu, MD
- Telefonnummer: 0086 13601958108
- E-post: pujun310@hotmail.com
-
Huvudutredare:
- Jun Bu, MD
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- Rekrytering
- West China Hospital of Sichuan University
-
Kontakt:
- Yong He, MD
- Telefonnummer: 0086 18980602038
- E-post: zznnyeah@163.com
-
Huvudutredare:
- Yong He, MD
-
Chengdu, Sichuan, Kina, 610072
- Rekrytering
- Sichuan Provincial People's Hospital
-
Kontakt:
- Jianhong Tao, DM
- Telefonnummer: 86-189 8183 8875
- E-post: Taojianhong06@medmail.com.cn
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina, 300211
- Rekrytering
- The Second Hospital of Tianjin Medical University
-
Kontakt:
- Tong Liu, MD
- Telefonnummer: 0086 13902183163
- E-post: liutongdoc@126.com
-
Huvudutredare:
- Tong Liu, MD
-
Tianjin, Tianjin Municipality, Kina, 300121
- Rekrytering
- Tianjin People's Hospital
-
Huvudutredare:
- Zhuhua Yao, MD
-
Kontakt:
- Zhuhua Yao, MD
- Telefonnummer: 0086 13902199877
- E-post: tjyzhpci@163.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina, 310006
- Rekrytering
- Zhejiang Provincial People's Hospital
-
Kontakt:
- Lihong Wang, MD
- Telefonnummer: 0086-13666690598
- E-post: wlhhz@hotmail.com
-
Suzhou, Zhejiang, Kina, 215006
- Rekrytering
- The First Affiliated Hospital of Soochow University
-
Kontakt:
- Tingbo Jiang, MD
- Telefonnummer: 0086-18906201122
- E-post: jiangtingbo6797@163.com
-
Wenzhou, Zhejiang, Kina, 325000
- Rekrytering
- The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU
-
Kontakt:
- lianpin Wu, MD
- E-post: 198019@wzhealth.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Fully understands the purposes, features, and methods of the study and the possible adverse reactions, and is voluntarily willing to participate in the study, and signs the informed consent form (ICF) before performing any study-specific assessment.
- Male or female participants between 18 and 80 years (inclusive, at the time of signing the ICF).
- Participants must satisfy either of the following criteria:
1) Have clinically evident atherosclerotic CV disease (ASCVD) 2) Meet at least two of the following criteria at screening/baseline, as evidenced by:
-
A history of Type 2 diabetes requiring treatment with medication,
-
Aged > 55 years (women) or > 50 years (men),
-
2 or more of the following atherosclerosis risk factors:
-
Current cigarette smoker
-
Hypertension
-
Estimated glomerular filtration rate (eGFR) 45 to 60 ml/min/1.73m2
4. Known coronary atherosclerosis as evidenced through coronary angiography or CCTA. The following criteria must be met on the core lab CCTA interpretation for the patient to be enrolled: at least one epicardial coronary artery with a lumen stenosis of 25% to 69%, total coronary NCPV is at least 75 mm3, Detectable low-attenuation composition in one or more individual plaques.
5. Female participants must be non-pregnant and non-lactating
6. Willing and able to comply with the requirements of protocol to the best of the participant's and investigator's knowledge.
-
Exclusion Criteria:
- Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.
- Previously received YN001.
- Any type of vaccination within 4 weeks prior to randomization, or any planned vaccination during the study treatment period
- Contraindication for CCTA
- 3 major epicardial coronary arteries with ≥ 70% or left main ≥50% stenosis.
- Acute MI that occurred within 4 weeks prior to randomization.
- PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.
- Clinically evident stroke or transient ischemic attack (TIA) within 6 months prior to randomization.
- Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months.
- Prior coronary artery bypass graft (CABG), aortic root surgery with coronary reimplantation, left ventricular assist device (LVAD) placement, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or heart transplantation, or a plan to undergo these procedures (CABG, aortic root surgery with coronary reimplantation, LVAD placement, SAVR, TAVR, or heart transplantation) during the study.
- New York Heart Association class III or IV or last known left ventricular ejection fraction (LVEF) was <40%.
- Carotid endarterectomy or stenting, peripheral arterial revascularization, or abdominal aortic aneurysm repair within 4 weeks prior to randomization.
- History of myopathy or myositis, or susceptibility to myopathy/rhabdomyolysis (e.g., family history of hereditary myopathy, etc.).
- History of severe myalgia attributed to statin therapy or other significant concern about statin side effects.
- Known gastrointestinal ulcers, inflammatory bowel disease, or gastrointestinal/rectal bleeding within 6 months prior to randomization.
- Evidence of unresolved major diseases 2 weeks prior to randomization or planned major surgery during the study that, in the investigator's judgement, may interfere with the investigational product administration or trial assessments.
- Presenting with history of malignancy (except in participants who have been disease-free >5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).
- Presence of any type of autoimmune disease.
- Allergy to multiple foods or drugs or known sensitivity to any components to be administered during dosing.
- Life expectancy is less than 1 year.
- Systolic blood pressure of ≥ 160 mmHg at final screening despite antihypertensive therapy.
- Triglycerides ≥ 400 mg/dL (4.5 mmol/L) at final screening.
- LDL-C > 100 mg/dL (2.6 mmol/L) at final screening.
- Active liver disease or hepatic dysfunction defined by any of alanine aminotransaminase (ALT), aspartate aminotransferase (AST), > 3 times upper limit of normal (ULN), or total bilirubin > 2 times ULN at final screening.
- Presence of renal dysfunction, defined by eGFR < 45 ml/min/1.73m2.
- Untreated or inadequately treated hypothyroidism.
- Poorly controlled Type 2 diabetes mellitus.
- A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).
- Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the participant to participate in this study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Dose 1 YN001/Placebo 40mg
Dose 1 YN001/Placobo 40mg will be administrated intravenously weekly |
Dose 1 YN001/Placebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
|
Experimentell: Dose 2 YN001/Placebo 20mg
Dose 2 YN001/Placebo 20mg will be administrated intravenously weekly |
YN001/Placebo 20mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
|
Placebo-jämförare: Dose 3 YN001/Placebo 0mg
Dose 3 YN001/Placebo 0mg will be administrated intravenously weekly |
YN001/Placebo 0mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Relative change from baseline in coronary NCPV at Week 13
Tidsram: Baseline to Week 13
|
Relative change in coronary NCPV from baseline to Week 13 as determined by coronary computed tomography angiography (CCTA) |
Baseline to Week 13
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 13
Tidsram: From baseline to Week 13
|
Absolute change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound. |
From baseline to Week 13
|
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9
Tidsram: From baseline to Week 9
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9 |
From baseline to Week 9
|
|
Relative change from baseline in carotid intima-media thickness (IMT) at Week 13
Tidsram: From baseline to Week 13
|
Relative change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound |
From baseline to Week 13
|
|
Relative change in the maximum thickness and area of carotid plaque at Week 9, and Week 13
Tidsram: From baseline to Week 9 and Week 13
|
Relative change in the maximum thickness and area of carotid plaque from baseline to Week 9, and Week 13 as determined by carotid ultrasound |
From baseline to Week 9 and Week 13
|
|
Relative change in coronary Percent Atheroma Volume (PAV) at Week 13
Tidsram: From baseline to Week 13
|
Relative change in coronary Percent Atheroma Volume (PAV) from baseline to Week 13 as determined by CCTA |
From baseline to Week 13
|
|
Relative change in coronary Low Attenuation Plaque Volume(LAPV) at Week 13
Tidsram: From baseline to week 13
|
Relative change in coronary LAPV from baseline to Week 13 as determined by CCTA. |
From baseline to week 13
|
|
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline at 48 week
Tidsram: From baseline to week 48
|
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline to Week 48 as determined by CCTA |
From baseline to week 48
|
|
Absolute change in coronary NCPV at week 13 and week 48
Tidsram: From baseline to week 13 and week 48
|
Absolute change in coronary NCPV from baseline to Week 13 and Week 48 as determined by CCTA |
From baseline to week 13 and week 48
|
|
Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)
Tidsram: From randomization to Week 96
|
Time to the first occurrence of the MACE, composite of CV death, myocardial infarction (MI), ischemic stroke, urgent coronary revascularization, or hospitalization for unstable angina |
From randomization to Week 96
|
|
The safety profile of YN001
Tidsram: From baseline to Week 13
|
Incidence of treatment emergent adverse event (TEAE)/serious adverse event (SAE)/adverse event of special interest (AESI) |
From baseline to Week 13
|
|
Immunogenicity (ADA) analysis
Tidsram: From baseline to Week 13
|
Incidence of anti-drug antibodies (ADA) formation |
From baseline to Week 13
|
|
Immunogenicity (APA) analysis
Tidsram: From baseline to Week 17
|
Incidence of anti-PEG antibodies (APA) formation |
From baseline to Week 17
|
|
YN001 concentrations analysis in plasma
Tidsram: From baseline to Week 13
|
Sparse blood samples will be collected, and these concentrations are intended to be pooled with other studies to develop/update pharmacometric models |
From baseline to Week 13
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Studierektor: Ying Chen, PhD, Beijing Inno Medicine Co., Ltd.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- YN001-203
- IND 157167 (Registeridentifierare: Beijing Inno Medicine Co., Ltd.)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .